Yasuhiro Oki
Overview
Explore the profile of Yasuhiro Oki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
164
Citations
4674
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cherng H, Alig S, Oki Y, Nastoupil L, Fayad L, Neelapu S, et al.
Blood Adv
. 2022 Nov;
7(7):1137-1145.
PMID: 36375046
Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP); however, one-third of patients experience refractory or relapsed disease. Studies comparing R-CHOP with modified...
2.
Westin J, Davis R, Feng L, Hagemeister F, Steiner R, Lee H, et al.
J Clin Oncol
. 2022 Aug;
41(4):745-755.
PMID: 35952327
Purpose: Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib...
3.
Landsburg D, Barta S, Ramchandren R, Batlevi C, Iyer S, Kelly K, et al.
Br J Haematol
. 2021 Aug;
195(2):201-209.
PMID: 34341990
Fimepinostat (CUDC-907), a first-in-class oral small-molecule inhibitor of histone deacetylase and phosphatidylinositol 3-kinase, demonstrated efficacy in a phase 1 study of patients with relapsed/refractory (R/R) diffuse large and high-grade B-cell...
4.
Kim W, Oki Y, Kim S, Yoon S, Ardeshna K, Lin Y, et al.
Ann Hematol
. 2021 Jul;
100(10):2529-2539.
PMID: 34304287
We conducted a phase II clinical trial to develop an autologous EBV-specific T cell product (baltaleucel T) for advanced, relapsed ENKTL. Among 47 patients who provided whole blood starting material...
5.
Evens A, Connors J, Younes A, Ansell S, Kim W, Radford J, et al.
Haematologica
. 2021 Jun;
107(5):1086-1094.
PMID: 34162178
Effective and tolerable treatments are needed for older patients with classical Hodgkin lymphoma. We report results for older patients with classical Hodgkin lymphoma treated in the large phase III ECHELON-1...
6.
Johnston P, Cashen A, Nikolinakos P, Beaven A, Barta S, Bhat G, et al.
Exp Hematol Oncol
. 2021 Feb;
10(1):15.
PMID: 33602316
Background: Belinostat is a histone deacetylase inhibitor approved for relapsed refractory peripheral T-cell lymphoma (PTCL). The primary objective of this study was to determine the maximum tolerated dose (MTD) of...
7.
Schaffer M, Chaturvedi S, Davis C, De Jong J, Aquino R, Oki Y, et al.
Cancer Treat Res Commun
. 2020 Nov;
25:100235.
PMID: 33188997
Introduction: This unplanned post-hoc analysis was based on data from the phase Ib DBL1002 study (NCT01569750) and evaluated the association between molecular biomarkers and clinical response to combined treatment with...
8.
Janku F, Park H, Call S, Madwani K, Oki Y, Subbiah V, et al.
Clin Cancer Res
. 2020 Oct;
26(21):5579-5587.
PMID: 33055173
Purpose: Preclinical and early clinical data suggested that combining histone deacetylase (HDAC) and mTOR inhibitors can synergistically inhibit Hodgkin lymphoma. Patients And Methods: During the dose-escalation study (ClinicalTrials.gov number: NCT01087554)...
9.
Huen A, Haverkos B, Zain J, Radhakrishnan R, Lechowicz M, Devata S, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32824175
Tenalisib (RP6530), a dual phosphoinositide 3-kinase δ/γ inhibitor was evaluated in a phase I/Ib study for maximum tolerated dose (MTD), pharmacokinetics, and efficacy in patients with relapsed/refractory peripheral and cutaneous...
10.
Kuhn F, Katsuragi S, Oki Y, Scholz C, Akai S, Groger H
Chem Commun (Camb)
. 2020 Feb;
56(19):2885-2888.
PMID: 32037430
In spite of the tremendous success of dynamic kinetic resolutions for a broad range of compound classes, tertiary alcohols and their corresponding esters have still remained as one of the...